AR047975A1 - Bloqueadores de kv1.5 para aumentar selectivamente la contractilidad auricular y tratar la insuficiencia cardiaca - Google Patents
Bloqueadores de kv1.5 para aumentar selectivamente la contractilidad auricular y tratar la insuficiencia cardiacaInfo
- Publication number
- AR047975A1 AR047975A1 ARP050100675A ARP050100675A AR047975A1 AR 047975 A1 AR047975 A1 AR 047975A1 AR P050100675 A ARP050100675 A AR P050100675A AR P050100675 A ARP050100675 A AR P050100675A AR 047975 A1 AR047975 A1 AR 047975A1
- Authority
- AR
- Argentina
- Prior art keywords
- atoms
- alkyl
- phenyl
- pyridyl
- substituted
- Prior art date
Links
- 206010019280 Heart failures Diseases 0.000 title abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 11
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 6
- -1 2-pyridin-3-ylethyl Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000004076 pyridyl group Chemical group 0.000 abstract 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- GTKIGDZXPDCIKR-UHFFFAOYSA-N 2-phenylbenzamide Chemical compound NC(=O)C1=CC=CC=C1C1=CC=CC=C1 GTKIGDZXPDCIKR-UHFFFAOYSA-N 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- IXKPEYHRIVQTCU-UHFFFAOYSA-N n-[(2,4-difluorophenyl)methyl]-2-[2-[[[2-(4-methoxyphenyl)acetyl]amino]methyl]phenyl]benzamide Chemical compound C1=CC(OC)=CC=C1CC(=O)NCC1=CC=CC=C1C1=CC=CC=C1C(=O)NCC1=CC=C(F)C=C1F IXKPEYHRIVQTCU-UHFFFAOYSA-N 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicacion 1: El uso de compuestos de las formulas (1) y/o (2), y/o sus sales fisiologicamente toleradas para producir un medicamento para la terapia o profilaxis de la insuficiencia cardíaca, en los que los significados son: R1 es alquilo que tiene 3, 4 o 5 átomos C o quinolinilo, R2 es alquilo que tiene 1, 2, 3,o 4 átomos C o ciclopropilo; R3 es fenilo o piridilo, en los que fenilo y piridinilo no están sustituidos o están sustituidos con 1 o 2 sustituyentes seleccionados entre el grupo que consiste en F, Cl, CF3, OCF3, alquilo que tiene 1, 2, o 3 átomos C y alcoxi que tiene 1, 2 o 3 átomos C; A es -CnH2n-; n es 0, 1 o 2; R4, R5, R6, y R7 son independientemente unos de otros hidrogeno, F, Cl, CF3, OCF3, CN, alquilo que tiene 1, 2 o 3 átomos C, alcoxi que tiene 1, 2 o 3 átomos C; B es -CmH2m-; m es 1 o 2; R8 es alquilo que tiene 2 o 3 átomos C, fenilo o piridilo, en los que fenilo y piridilo no están sustituidos o están sustituidos con 1 o 2 sustituyentes seleccionados entre el grupo que consiste en F, Cl, CF3, OCF3, alquilo que tiene 1, 2 o 3 átomos C y alcoxi que tiene 1, 2 o 3 átomos C; R9 es C(O)OR10 o COR10; R10 es -CxH2x-R11; x es 0, 1 o 2; R11 es fenilo, en los que el fenilo no está sustituido o está sustituido con 1 o 2 sustituyentes seleccionados entre el grupo que consiste en F, Cl, CF3, OCF3, alquilo que tiene 1, 2, o 3 átomos C y alcoxi que tiene 1, 2 o 3 átomos C. Reivindicacion 5: La composicion que comprende los compuestos de las formulas (1) y/o (2), y/o una de sus sales fisiologicamente toleradas de acuerdo con la reivindicacion 1, para producir un medicamento para la terapia o profilaxis de la insuficiencia cardíaca, en el que los compuestos de las formulas (1) y/o (2) se seleccionan entre el grupo de N-(2-piridin-3-iletil)-2'-{[2-(4-metoxifenil)acetilamino]metil}bifenil-2-carboxamida; N-(2-(2-piridil)etil)-2'-(benciloxicarbonilaminometil)bifenil-2-carboxamida; N-(2,4-difluorobencil)-2'-{[2-(4-metoxifenil)acetilamino]metil}-bifenil-2- carboxamida; N-(2-(2-piridil)etil)-(S)-2'-(a-metilbenciloxicarbonilaminometil)bifenil-2-carboxamida; 2-(butil-1-sulfonilamino)-N-[1(R)-(6-metoxipiridin-3-il)propil]benzamida; 2-(butil-1-sulfonilamino)-N-(ciclopropilpiridin-3-ilmetil)-5-metil- benzamida; (S)-5-fluoro-2-(quinolina-8-sulfonilamino)-N-(1-fenilpropil)benzamida y/o sus sales fisiologicamente toleradas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004009931A DE102004009931A1 (de) | 2004-02-26 | 2004-02-26 | Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR047975A1 true AR047975A1 (es) | 2006-03-15 |
Family
ID=34853866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050100675A AR047975A1 (es) | 2004-02-26 | 2005-02-24 | Bloqueadores de kv1.5 para aumentar selectivamente la contractilidad auricular y tratar la insuficiencia cardiaca |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070043091A1 (es) |
| EP (1) | EP1720549A1 (es) |
| JP (1) | JP2007523926A (es) |
| KR (1) | KR20060125862A (es) |
| CN (1) | CN1921855A (es) |
| AR (1) | AR047975A1 (es) |
| AU (1) | AU2005218731A1 (es) |
| BR (1) | BRPI0508054A (es) |
| CA (1) | CA2557263A1 (es) |
| DE (1) | DE102004009931A1 (es) |
| IL (1) | IL177255A0 (es) |
| PE (1) | PE20051138A1 (es) |
| TW (1) | TW200536522A (es) |
| UY (1) | UY28777A1 (es) |
| WO (1) | WO2005084675A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1815027A1 (en) * | 2004-11-22 | 2007-08-08 | Integragen | Human obesity susceptibility gene encoding potassium ion channels and uses thereof |
| EP2012758A2 (en) * | 2006-04-27 | 2009-01-14 | Sanofi-Aventis Deutschland GmbH | Inhibitors of the task-1 and task-3 ion channel |
| US9101616B2 (en) * | 2009-05-29 | 2015-08-11 | Raqualia Pharma Inc. | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers |
| WO2010139585A2 (en) * | 2009-06-03 | 2010-12-09 | Sanofi-Aventis Deutschland Gmbh | Crystalline phases of 2'-{[2-(4-methoxy-phenyl)-acetylamino]-methyl}-biphenyl-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide |
| CN107033064B (zh) * | 2017-04-28 | 2019-07-09 | 西安医学院 | 一种3-(吗啉取代芳亚胺基)吲哚类化合物及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2128644C1 (ru) * | 1993-12-27 | 1999-04-10 | Эйсай Ко., Лтд. | Производные антраниловой кислоты или их фармакологически приемлемые соли, промежуточные продукты для их получения и лекарственный препарат на их основе |
| US5935945A (en) * | 1996-10-31 | 1999-08-10 | Merck & Co., Inc. | Methods of treating or preventing cardiac arrhythmia |
| JP3786579B2 (ja) * | 1998-07-08 | 2006-06-14 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 硫黄置換スルホニルアミノカルボン酸ｎ−アリールアミド、それらの製造、それらの使用、及びそれらを含む医薬製剤 |
| US6129802A (en) | 1998-11-05 | 2000-10-10 | Stephen Key Design, Llc | Rotatable label system and method of constructing same |
| US6531495B1 (en) * | 1999-10-02 | 2003-03-11 | Aventis Pharma Deutschland Gmbh | 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them |
| DE19947457A1 (de) * | 1999-10-02 | 2001-04-05 | Aventis Pharma Gmbh | 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen |
| DE10060809A1 (de) * | 2000-12-07 | 2002-06-20 | Aventis Pharma Gmbh | Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker |
| DE10121002A1 (de) * | 2001-04-28 | 2002-11-14 | Aventis Pharma Gmbh | Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10121003A1 (de) * | 2001-04-28 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10128331A1 (de) * | 2001-06-12 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10312073A1 (de) * | 2003-03-18 | 2004-09-30 | Aventis Pharma Deutschland Gmbh | 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxy-pyridin-3yl)-propyl]-benzamid, dessen Verwendung als Medikament sowie dieses enthaltende pharmazeutische Zubereitungen |
-
2004
- 2004-02-26 DE DE102004009931A patent/DE102004009931A1/de not_active Withdrawn
-
2005
- 2005-02-12 BR BRPI0508054-1A patent/BRPI0508054A/pt not_active IP Right Cessation
- 2005-02-12 CN CNA2005800054867A patent/CN1921855A/zh active Pending
- 2005-02-12 KR KR1020067017127A patent/KR20060125862A/ko not_active Withdrawn
- 2005-02-12 AU AU2005218731A patent/AU2005218731A1/en not_active Abandoned
- 2005-02-12 CA CA002557263A patent/CA2557263A1/en not_active Abandoned
- 2005-02-12 WO PCT/EP2005/001422 patent/WO2005084675A1/de not_active Ceased
- 2005-02-12 JP JP2007500093A patent/JP2007523926A/ja not_active Abandoned
- 2005-02-12 EP EP05707351A patent/EP1720549A1/de not_active Withdrawn
- 2005-02-15 PE PE2005000178A patent/PE20051138A1/es not_active Application Discontinuation
- 2005-02-24 TW TW094105508A patent/TW200536522A/zh unknown
- 2005-02-24 AR ARP050100675A patent/AR047975A1/es unknown
- 2005-02-25 UY UY28777A patent/UY28777A1/es unknown
-
2006
- 2006-08-02 IL IL177255A patent/IL177255A0/en unknown
- 2006-08-24 US US11/466,791 patent/US20070043091A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PE20051138A1 (es) | 2006-02-06 |
| CN1921855A (zh) | 2007-02-28 |
| CA2557263A1 (en) | 2005-09-15 |
| IL177255A0 (en) | 2006-12-10 |
| AU2005218731A1 (en) | 2005-09-15 |
| US20070043091A1 (en) | 2007-02-22 |
| BRPI0508054A (pt) | 2007-07-17 |
| EP1720549A1 (de) | 2006-11-15 |
| KR20060125862A (ko) | 2006-12-06 |
| UY28777A1 (es) | 2005-09-30 |
| WO2005084675A1 (de) | 2005-09-15 |
| JP2007523926A (ja) | 2007-08-23 |
| TW200536522A (en) | 2005-11-16 |
| DE102004009931A1 (de) | 2005-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR045083A1 (es) | Productos aril-heteroaromaticos, composiciones que los contienen y utilizacion como medicamento | |
| AR039127A1 (es) | Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento | |
| AR032781A1 (es) | Amidas ariladas de acidos furan- y tiofencarboxilicos, composiciones farmaceuticas, su utilizacion para la preparacion de medicamento como tambien las composiciones farmaceuticas que las contienen | |
| PE20021066A1 (es) | Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, procedimiento para su preparacion, asi como preparados farmaceuticos que las contienen | |
| PE20030968A1 (es) | Derivados de 5-feniltiazol como inhibidores de cinasas | |
| AR111466A1 (es) | Inhibidores de hdac6 selectivos | |
| AR054799A1 (es) | Derivados de oxindol | |
| NZ717119A (en) | Aryl-or heteroaryl-substituted benzene compounds | |
| JP2010517946A5 (es) | ||
| AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
| AR042342A1 (es) | Derivados de pirazina que presentan efecto inhibidor selectivo sobre gsk3, proceso de preparacion y formulaciones farmaceuticas que los contienen | |
| ES2213007T3 (es) | Derivados de 4,5-diaril-3(2h)-furanona como inhibidores de la ciclooxigenasa-2. | |
| RU2394031C2 (ru) | Соли четвертичного аммония в качестве антагонистов м3 | |
| KR920006322A (ko) | 벤젠, 피리딘 및 피리미딘 유도체 | |
| SE9703375D0 (sv) | A new combination | |
| AR053554A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
| AR044830A1 (es) | Derivados de 4,5 diaril -3-heterociclilpirazin- 2- ester | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| PE20071224A1 (es) | Derivados de aminometilpiridina como antagonistas de los receptores cannabinoides 1 (cb1) | |
| CO6260092A2 (es) | Compuesto de nicotinamida sustituida y su uso en productos farmaceuticos | |
| JP2020504122A5 (es) | ||
| AR047975A1 (es) | Bloqueadores de kv1.5 para aumentar selectivamente la contractilidad auricular y tratar la insuficiencia cardiaca | |
| DK78995A (da) | Anvendelse af visse substituerede arylalkylaminer til fremstilling af et lægemiddel med neurobeskyttende virkning | |
| DK0461958T3 (da) | 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxanderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i terapien | |
| NZ332030A (en) | Sulfonamide substituted chromans, processes for their preparation, their use as a medicament and pharmaceutical preparations comprising them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |